420 related articles for article (PubMed ID: 36497266)
21. Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them.
Borogovac A; Siddiqi T
Cancer Drug Resist; 2024; 7():18. PubMed ID: 38835348
[TBL] [Abstract][Full Text] [Related]
22. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
23. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
24. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
25. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
Front Immunol; 2021; 12():619069. PubMed ID: 34108958
[TBL] [Abstract][Full Text] [Related]
26. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
[TBL] [Abstract][Full Text] [Related]
28. Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.
Felices M; Kodal B; Hinderlie P; Kaminski MF; Cooley S; Weisdorf DJ; Vallera DA; Miller JS; Bachanova V
Blood Adv; 2019 Mar; 3(6):897-907. PubMed ID: 30890546
[TBL] [Abstract][Full Text] [Related]
29. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
Veuillen C; Aurran-Schleinitz T; Castellano R; Rey J; Mallet F; Orlanducci F; Pouyet L; Just-Landi S; Coso D; Ivanov V; Carcopino X; Bouabdallah R; Collette Y; Fauriat C; Olive D
J Clin Immunol; 2012 Jun; 32(3):632-46. PubMed ID: 22318393
[TBL] [Abstract][Full Text] [Related]
30. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
31. Dysregulated Expression of Tim-3 and NKp30 Receptors on NK Cells of Patients with Chronic Lymphocytic Leukemia.
Hadadi L; Hafezi M; Amirzargar AA; Sharifian RA; Abediankenari S; Asgarian-Omran H
Oncol Res Treat; 2019; 42(4):202-208. PubMed ID: 30870839
[TBL] [Abstract][Full Text] [Related]
32. Cellular Therapy Advances in Chronic Lymphocytic Leukemia and Richter's Syndrome.
Bajwa A; Voorhees TJ; Kittai AS
Curr Probl Cancer; 2022 Feb; 46(1):100827. PubMed ID: 34991902
[TBL] [Abstract][Full Text] [Related]
33. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
Front Immunol; 2021; 12():608625. PubMed ID: 33790890
[TBL] [Abstract][Full Text] [Related]
34. Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia.
Ziegler HW; Kay NE; Zarling JM
Int J Cancer; 1981 Mar; 27(3):321-7. PubMed ID: 6169660
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
36. CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
Todorovic Z; Todorovic D; Markovic V; Ladjevac N; Zdravkovic N; Djurdjevic P; Arsenijevic N; Milovanovic M; Arsenijevic A; Milovanovic J
Curr Oncol; 2022 May; 29(5):3647-3657. PubMed ID: 35621683
[TBL] [Abstract][Full Text] [Related]
37. Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells.
Sánchez-Martínez D; Lanuza PM; Gómez N; Muntasell A; Cisneros E; Moraru M; Azaceta G; Anel A; Martínez-Lostao L; Villalba M; Palomera L; Vilches C; García Marco JA; Pardo J
Front Immunol; 2016; 7():454. PubMed ID: 27833611
[TBL] [Abstract][Full Text] [Related]
38. Driving Out Chronic Lymphocytic Leukemia With CAR T Cells.
Kharfan-Dabaja MA; Yassine F; Gadd ME; Qin H
Transplant Cell Ther; 2022 Jan; 28(1):5-17. PubMed ID: 34656807
[TBL] [Abstract][Full Text] [Related]
39. Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V; Perutelli F; Salvetti C; Boccellato E; Boccadoro M; Vitale C; Coscia M
Front Immunol; 2020; 11():594556. PubMed ID: 33312177
[TBL] [Abstract][Full Text] [Related]
40. Reduced expansion of CD94/NKG2C
Puiggros A; Blanco G; Muntasell A; Rodríguez-Rivera M; Nonell L; Altadill M; Puigdecanet E; Arnal M; Calvo X; Gimeno E; Abella E; Abrisqueta P; Bosch F; Yélamos J; Ferrer A; López-Botet M; Espinet B
Int J Lab Hematol; 2021 Oct; 43(5):1032-1040. PubMed ID: 33615729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
